Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.49 |
| ▸ | CA2 | P00918 | 12/20 | 0.49 |
| ▸ | CA12 | O43570 | 9/20 | 0.49 |
| ▸ | CA9 | Q16790 | 9/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604218 | 0.95 | CA1 (0.56) | CA1CA2CA12CA9CA5A | |
| SCHEMBL4604757 | 0.94 | CA1 (0.48) | CA1CA2CA12CA9CA5A | |
| SCHEMBL4603342 | 0.90 | CA1 (0.48) | CA1CA2CA12CA9CA5A | |
| SCHEMBL4605031 | 0.90 | CTSD (0.54) | CA1CA2CA12CA9CTSD | |
| SCHEMBL4602141 | 0.89 | CA1 (0.51) | CA1CA2CA12CA9CA5A | |
| SCHEMBL4604206 | 0.88 | CA1 (0.55) | CA1CA2CA12CA9CA5A | |
| SCHEMBL4603727 | 0.87 | CA1 (0.49) | CA1CA2CA12CA9CA5A | |
| SCHEMBL4603630 | 0.87 | CA1 (0.58) | CA1CA2CA12CA9CA5A | |
| SCHEMBL2639500 | 0.86 | CTSD (0.51) | CA1CA2CA12CA9CA5A | |
| SCHEMBL4604831 | 0.86 | CA1 (0.58) | CA1CA2CA12CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940781-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7388111-B2 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC (US) | 2008-06-17 | — | — | US | disclosed |
| WO-2007045573-A1 | PHENYL-ACETAMIDE NNRT INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-26 | — | — | WO | disclosed |
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088053-A1 | Non-nucleoside reverse transcriptase inhibitors | SAMHD1, QTRT1, RTF1 | CA1 4746/4885CA2 4750/4885CA12 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.